Literature DB >> 16546472

The utility of fasting glucose for detection of prediabetes.

Cynthia Cheng1, Harvey Kushner, Bonita E Falkner.   

Abstract

Treatment of prediabetes attenuates progression to type 2 diabetes mellitus. The American Diabetes Association (ADA) previously defined prediabetes as either impaired fasting glucose (IFG) = 6.1 to 6.9 mmol/L (110-125 mg/dL) and/or impaired glucose tolerance (IGT) (2-hour postload glucose of 7.8-11.0 mmol/L [140-199 mg/dL]). For practical reasons, fasting plasma glucose (FPG) is commonly used for diabetes screening. Recently, the ADA lowered the fasting glucose threshold value for IFG from 110 to 100 mg/dL. Our objective was to determine the utility of FPG alone for detecting prediabetes in African Americans. Oral glucose tolerance test (OGTT) data from a cohort of 304 young adult African American men and women were examined. We calculated prediabetes prevalence using the previous ADA criteria and examined the effect of lowering the IFG threshold value for IFG to 100 mg/dL. The prediabetes prevalence in this cohort using the previous ADA criteria was 20.4% (n = 62). Of the 62 cases, 8 had IFG, 45 had IGT, and 9 had IFG together with IGT. Fasting plasma glucose testing alone detected 17 (27.4%) prediabetic cases, whereas a complete OGTT detected 54 (87.1%). Lowering the IFG threshold value to FPG = 100 mg/dL identified 13 of the 45 IGT-only cases. However, this lower IFG threshold increased prediabetes prevalence in the overall cohort from 20.4% to 31.9%. In conclusion, in young adult African Americans, an ethnic group at high risk for developing diabetes, FPG testing alone may be inadequate for diagnosing prediabetes. Until alternative strategies are identified, an OGTT is presently the best method for detecting the prediabetic condition in these high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546472     DOI: 10.1016/j.metabol.2005.10.003

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  16 in total

1.  Endothelin-1 response to glucose and insulin among African Americans.

Authors:  Stephanie DeLoach; Yonghong Huan; Constantine Daskalakis; Bonita Falkner
Journal:  J Am Soc Hypertens       Date:  2010-08-21

Review 2.  Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; Gabriel Gimenez-Perez; Didac Mauricio; Marta Roqué I Figuls; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2017-12-04

Review 3.  Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; David Peick Sonne; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2016-10-17

Review 4.  Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions.

Authors:  Mehrul Hasnain; W Victor R Vieweg; Sonja K Fredrickson
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

Review 5.  Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; Jesper Krogh; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2016-04-21

Review 6.  Screening for Diabetes and Prediabetes.

Authors:  Daisy Duan; Andre P Kengne; Justin B Echouffo-Tcheugui
Journal:  Endocrinol Metab Clin North Am       Date:  2021-07-12       Impact factor: 4.748

Review 7.  Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; David P Sonne; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2017-05-10

8.  The route to diabetes: Loss of complexity in the glycemic profile from health through the metabolic syndrome to type 2 diabetes.

Authors:  Juan Churruca; Luis Vigil; Esther Luna; Julian Ruiz-Galiana; Manuel Varela
Journal:  Diabetes Metab Syndr Obes       Date:  2008-08-11       Impact factor: 3.168

9.  Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

Authors:  Kasper S Madsen; Yuan Chi; Maria-Inti Metzendorf; Bernd Richter; Bianca Hemmingsen
Journal:  Cochrane Database Syst Rev       Date:  2019-12-03

10.  Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.

Authors:  Bernd Richter; Bianca Hemmingsen; Maria-Inti Metzendorf; Yemisi Takwoingi
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.